Trial Outcomes & Findings for Actis Total Hip System 2 Year Follow-up (NCT NCT02783274)

NCT ID: NCT02783274

Last Updated: 2025-08-15

Results Overview

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

266 participants

Primary outcome timeframe

2 Years

Results posted on

2025-08-15

Participant Flow

All eligible patients were asked if they were interested in study participation. 266 Hips in 266 Patients were enrolled into the study.

Unit of analysis: Hips

Participant milestones

Participant milestones
Measure
Actis Total Hip System
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Overall Study
STARTED
266 266
Overall Study
Treated
255 255
Overall Study
Total Hip Replacement Participants (THA)
232 232
Overall Study
Hemi-hip Replacement Participants (HHA)
23 23
Overall Study
COMPLETED
191 191
Overall Study
NOT COMPLETED
75 75

Reasons for withdrawal

Reasons for withdrawal
Measure
Actis Total Hip System
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Overall Study
Withdrawal by Subject
16
Overall Study
Physician Decision
6
Overall Study
Death
9
Overall Study
Lost to Follow-up
22
Overall Study
Other
22

Baseline Characteristics

All implanted participants (n=255)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Actis Total Hip System
n=255 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Age, Continuous
62.6 Years
STANDARD_DEVIATION 11.66 • n=5 Participants • All implanted participants (n=255)
Sex: Female, Male
Female
119 Participants
n=5 Participants • Implanted Participants
Sex: Female, Male
Male
136 Participants
n=5 Participants • Implanted Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants
n=5 Participants • Implanted Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
247 Participants
n=5 Participants • Implanted Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
Black or African American
20 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
White
231 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
More than one race
2 Participants
n=5 Participants • Implanted Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Acute Fracture
22 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Avascular Necrosis
8 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Degenerative Joint Disease
41 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Hip Dysplasia
2 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Osteoarthritis
179 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Rheumatoid Arthritis
1 Participants
n=5 Participants • Implanted Participants
Implanted Participant Primary Diagnosis
Other
2 Participants
n=5 Participants • Implanted Participants

PRIMARY outcome

Timeframe: 2 Years

Population: All implanted participants who attended their 2-year clinical evaluation

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=166 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Harris Hip Score- THA Subjects Per Protocol at 2 Years
95.7 units on a scale
Standard Deviation 9.3

PRIMARY outcome

Timeframe: 2 Years

Population: All implanted participants who attended their 2-year clinical evaluation

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=5 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Harris Hip Score- HHA Subjects Per Protocol at 2 Years
83.2 units on a scale
Standard Deviation 15.3

SECONDARY outcome

Timeframe: 3 months

Population: All implanted participants who attended their 3-month clinical evaluation

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=189 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Harris Hip Score- THA Subjects Per Protocol at 3 Months
93.5 Units on a scale
Standard Deviation 8.7

SECONDARY outcome

Timeframe: 3 months

Population: All implanted participants who attended their 3-month clinical evaluation

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=9 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Harris Hip Score- HHA Subjects Per Protocol at 3 Months
85.3 units on a scale
Standard Deviation 14.3

SECONDARY outcome

Timeframe: 1 Year

Population: All implanted participants who attended their 1-year clinical evaluation

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=186 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Harris Hip Score- THA Subjects Per Protocol at 1 Year
95.7 Units on a scale
Standard Deviation 9.0

SECONDARY outcome

Timeframe: 1 Year

Population: All implanted participants who attended their 1-year clinical evaluation

The Harris Hip Score (HHS) is a standardized tool used to evaluate hip pain, function, and mobility. The HHS is score from 0 to 100, with higher scores indicating better outcomes. A score of less than 70 is considered poor, 70-80 is fair, 80-90 is good, 90-100 is excellent.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=5 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Harris Hip Score- HHA Subjects Per Protocol at 1 Year
85.8 units on a scale
Standard Deviation 12.6

SECONDARY outcome

Timeframe: 2 Years

Population: All THA implanted Participants

Device survivorship at 2 years post-operatively is a secondary endpoint in this study. A revision is defined as a revision for any reason and device survival is defined as the lack of revision. A 2-year Kaplan-Meier survivorship estimate of the Actis Hip System in implanted hips is provided.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=255 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Post-Operative 2-Year Device Survivorship- THA Subjects Safety Population
97.7 Percentage of hip Implants
Interval 94.5 to 99.0

SECONDARY outcome

Timeframe: 2 Years

Population: All THA Implanted Participants

A stem revision is defined as any stem revision for any reason and device survival is defined as the lack of revision. A 2-year Kaplan-Meier survivorship estimate of the Actis Hip System in implanted hips is provided.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=255 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Post-Operative 2-Year Femoral Stem Survivorship- THA Subjects Safety Population
99.6 Percentage of hip Implants
Interval 96.9 to 99.9

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Acetabular cup version is the angle formed between the axis of the implant and the coronal plane of the body. Acetabular version typically ranges between 11.5 and 28.5 degrees.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=166 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Acetabular Shell Version at 2-years Postoperatively- THA Subjects Per Protocol
25.9 Degrees
Standard Deviation 3.89

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Acetabular cup inclination is the angle between the longitudinal axis of the patient and a perpendicular line to the major axis of the cup projection. The target acetabular cup inclination is between 30-50 degrees

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=16 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Acetabular Shell Inclination at 2-years Postoperatively- THA Subjects Per Protocol
39.9 Degrees
Standard Deviation 4.87

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Number of participants with greater than (\>) 4 degrees change in acetabular cup inclination angle at 2 years postoperatively was reported.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With >4 Degrees Change in Acetabular Cup Inclination Angle at 2 Years Postoperatively - THA Subjects
1 Participants
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Number of participants with acetabular shell migration \>2mm at 2 years postoperatively were reported. Acetabular migration is the superior migration of the implant within the pelvic bone.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With Acetabular Shell Migration >2mm at 2 Years Postoperatively - THA Subjects Per Protocol
0 Participants
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Radiolucent lines are seen on x-rays and represent an area that is absent of bone. Radiolucent lines seen adjacent to an implant may suggest a lack on bone ingrowth or possible loosening of the implant. Radiolucent lines greater than 1mm wide were considered reportable for this study.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Acetabular Radiolucent Lines- THA Subjects Per Protocol
5 Hips
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Osteolysis is seen on x-rays and represent an area where bone has been resorbed by the body in response to small particles of debris that are created as an implant wears over time. Osteolysis greater than 5mm was considered to be reportable for this study.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Acetabular Osteolysis- THA Subjects Per Protocol
0 Hips
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Acetabular sclerotic lines are seen on x-rays and are radio-dense areas of bone that have remodeled due to loads close to the implant.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Acetabular Sclerotic Lines- THA Subjects Per Protocol
38 Hips
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Acetabular Cup Porous Coating Integrity is defined as the presence of one or more beads of the porous coating observed away from the component in the soft tissue adjacent to the device.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Acetabular Porous Coating Integrity- THA Subjects Per Protocol
0 Hips
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral stem position is categorized as neutral, valgus, or varus. A neutral stem is centered within the femoral canal that runs through the center of the femur's long axis. A valgus femoral stem is positioned slightly towards the medial side of the femoral canal, and a varus femoral stem is positioned slightly towards the lateral side of the femoral canal.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Position- THA Subjects Per Protocol
Neutral
160 Hips
Interval 4.87 to
Femoral Stem Position- THA Subjects Per Protocol
Valgus
3 Hips
Interval 4.87 to
Femoral Stem Position- THA Subjects Per Protocol
Varus
5 Hips
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral stem position is categorized as neutral, valgus, or varus. A neutral stem is centered within the femoral canal that runs through the center of the femur's long axis. A valgus femoral stem is positioned slightly towards the medial side of the femoral canal, and a varus femoral stem is positioned slightly towards the lateral side of the femoral canal.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Position- HHA Subjects Per Protocol
Neutral
5 Hips
Interval 4.87 to
Femoral Stem Position- HHA Subjects Per Protocol
Valgus
0 Hips
Interval 4.87 to
Femoral Stem Position- HHA Subjects Per Protocol
Varus
1 Hips
Interval 4.87 to

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Number of participants with femoral stem tilt were reported. Femoral stem tilt is a measurement taken at each post-operative year and compared against baseline images collected at 6-weeks post-operative. The measurement captures changes in the position of the femoral stem over time.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With Femoral Stem Tilt - THA Subjects Per Protocol
1 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Number of participants with femoral stem tilt were reported. Femoral stem tilt is a measurement taken at each post-operative year and compared against baseline images collected at 6-weeks post-operative. The measurement captures changes in the position of the femoral stem over time.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With Femoral Stem Tilt- HHA Subjects Per Protocol
0 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral stem subsidence is the inferior movement of the stem within the femoral canal. Subsidence greater than 2 mm was considered reportable for this study.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With Femoral Stem Subsidence- THA Subjects Per Protocol
0 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral stem subsidence is the inferior movement of the stem within the femoral canal. Subsidence greater than 2 mm was considered reportable for this study.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With Femoral Stem Subsidence- HHA Subjects Per Protocol
0 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Heterotopic ossification is the abnormal formation of bone in soft tissues, such as muscles, tendons, or ligaments and can occur around the hip joint, leading to pain, stiffness, and restricted range of motion. It is grade as Class 0 through Class IV, with Class 0 being least impactful and Class IV being most impactful.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Heterotopic Ossification- THA Subjects Per Protocol
Class 0
98 Hips
Femoral Stem Heterotopic Ossification- THA Subjects Per Protocol
Class III
3 Hips
Femoral Stem Heterotopic Ossification- THA Subjects Per Protocol
Class I
55 Hips
Femoral Stem Heterotopic Ossification- THA Subjects Per Protocol
Class II
11 Hips
Femoral Stem Heterotopic Ossification- THA Subjects Per Protocol
Unable to Assess
1 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Heterotopic ossification is the abnormal formation of bone in soft tissues, such as muscles, tendons, or ligaments and can occur around the hip joint, leading to pain, stiffness, and restricted range of motion. It is grade as Class 0 through Class IV, with Class 0 being least impactful and Class IV being most impactful.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Heterotopic Ossification- HHA Subjects Per Protocol
Class 0
2 Hips
Femoral Stem Heterotopic Ossification- HHA Subjects Per Protocol
Class I
2 Hips
Femoral Stem Heterotopic Ossification- HHA Subjects Per Protocol
Class II
0 Hips
Femoral Stem Heterotopic Ossification- HHA Subjects Per Protocol
Class III
2 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Radiolucencies are seen on x-rays and represent an area that is absent of bone. Radiolucent lines seen adjacent to an implant may suggest a lack of bone ingrowth into the implant or possible loosening of the implant.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Radiolucent Lines- THA Subjects Per Protocol
1 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Radiolucencies are seen on x-rays and represent an area that is absent of bone. Radiolucent lines seen adjacent to an implant may suggest a lack of bone ingrowth into the implant or possible loosening of the implant.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Radiolucent Lines- HHA Subjects Per Protocol
0 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Osteolysis is seen on x-rays and represent an area where bone has been resorbed by the body in response to small particles of debris that are created as an implant wears over time. Osteolysis greater than 5mm was considered to be reportable for this study.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Osteolysis- THA Subjects Per Protocol
0 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Osteolysis is seen on x-rays and represent an area where bone has been resorbed by the body in response to small particles of debris that are created as an implant wears over time. Osteolysis greater than 5mm was considered to be reportable for this study.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Osteolysis- HHA Subjects Per Protocol
0 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Sclerotic lines are seen on x-rays and are radio-dense areas of bone that have remodeled due to loads close to the implant.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Sclerotic Lines- THA Subjects Per Protocol
102 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Sclerotic lines are seen on x-rays and are radio-dense areas of bone that have remodeled due to loads close to the implant.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Sclerotic Lines- HHA Subjects Per Protocol
5 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Acetabular Cup Porous Coating Integrity is defined as the presence of one or more beads of the porous coating observed away from the component in the soft tissue adjacent to the device.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Porous Coating Integrity- THA Subjects Per Protocol
0 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral Stem Porous Coating Integrity is defined as the presence of one or more beads of the porous coating observed away from the component in the soft tissue adjacent to the device.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Porous Coating Integrity- HHA Subjects Per Protocol
0 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral calcar resorption occurs when the bone around the prosthesis is partially shielded from bearing loads and begins to resorb

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Calcar Resorption- THA Subjects Per Protocol
73 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Femoral calcar resorption occurs when the bone around the prosthesis is partially shielded from bearing loads and begins to resorb

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Calcar Resorption- HHA Subjects Per Protocol
3 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Near the top of the femur is a region of bone called the calcar femorale that provides strength to the femur when compressive forces are applied. During preparation of the femur to receive the femoral implant there is the possibility of fractures occurring in this region.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=168 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Calcar Fracture- THA Subjects Per Protocol
3 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: All implanted participants with radiographs on file at the 2-year study visit

Near the top of the femur is a region of bone called the calcar femorale that provides strength to the femur when compressive forces are applied. During preparation of the femur to receive the femoral implant there is the possibility of fractures occurring in this region.

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=6 Hips
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Femoral Stem Calcar Fracture- HHA Subjects Per Protocol
0 Hips

SECONDARY outcome

Timeframe: 2 Years

Population: Implanted subjects who attended the 2-year clinic visit and answered this question.

The number of subjects who perceived a Leg Length Discrepancy at Two Years

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=163 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Perceived Leg Length Discrepancy- THA Subjects Per Protocol
11 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: Implanted subjects who attended the 2-year clinic visit and answered this question.

The number of subjects who perceived a Leg Length Discrepancy at Two Years

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=2 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Perceived Leg Length Discrepancy- HHA Subjects Per Protocol
0 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: Implanted subjects with a 2-year radiograph on file

True LLD is defined as a difference of 3 cm or greater as reviewed via postoperative radiographs. The measurement is the distance between the superior-most aspects of the left and right femoral heads

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=163 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With True Leg Length Discrepancy- THA Subjects Per Protocol
0 Participants

SECONDARY outcome

Timeframe: 2 Years

Population: Implanted subjects with a 2-year radiograph on file

True LLD is defined as a difference of 3 cm or greater as reviewed via postoperative radiographs. The measurement is the distance between the superior-most aspects of the left and right femoral heads

Outcome measures

Outcome measures
Measure
Actis Total Hip System
n=2 Participants
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Number of Participants With True Leg Length Discrepancy- HHA Subjects Per Protocol
0 Participants

Adverse Events

Actis Total Hip System

Serious events: 8 serious events
Other events: 22 other events
Deaths: 9 deaths

Serious adverse events

Serious adverse events
Measure
Actis Total Hip System
n=255 participants at risk
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Infections and infestations
Wound Abscess
0.39%
1/255 • Number of events 2 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Infections and infestations
Post procedural infection
0.78%
2/255 • Number of events 2 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Injury, poisoning and procedural complications
Wound decomposition
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Cardiac disorders
Cardiac arrest
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Infections and infestations
Medical device site joint infection
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Injury, poisoning and procedural complications
Joint dislocation
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Product Issues
Device dislocation
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Product Issues
Device failure
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Injury, poisoning and procedural complications
Wound dehiscence
0.39%
1/255 • Number of events 1 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed

Other adverse events

Other adverse events
Measure
Actis Total Hip System
n=255 participants at risk
The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
Musculoskeletal and connective tissue disorders
Arthralgia
3.1%
8/255 • Number of events 12 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Injury, poisoning and procedural complications
Joint dislocation
2.0%
5/255 • Number of events 7 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Injury, poisoning and procedural complications
Fall
1.2%
3/255 • Number of events 3 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Musculoskeletal and connective tissue disorders
Bursitis
0.78%
2/255 • Number of events 2 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
General disorders
Impaired healing
0.78%
2/255 • Number of events 2 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
General disorders
Pyrexia
0.78%
2/255 • Number of events 2 • Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed
Adverse events were collected throughout the course of the study and continued until the 2-year interval when the study closed

Additional Information

Kirstin Cosgrove

Johnson & Johnson MedTech

Phone: +1 574 4049398

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60